<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02926950</url>
  </required_header>
  <id_info>
    <org_study_id>EFC14834</org_study_id>
    <secondary_id>2016-001800-49</secondary_id>
    <secondary_id>U1111-1181-6145</secondary_id>
    <nct_id>NCT02926950</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To demonstrate the superiority of sotagliflozin versus placebo on hemoglobin A1c (HbA1c)
      reduction in patients with type 2 diabetes (T2D) who have inadequate glycemic control with
      metformin.

      Secondary Objectives:

        -  To compare sotagliflozin versus placebo for:

        -  Change from baseline in 2-hour postprandial glucose (PPG) following a mixed meal.

        -  Change from baseline in fasting plasma glucose (FPG);

        -  Change from Baseline in systolic blood pressure (SBP) for patients with baseline SBP
           ≥130 mmHg;

        -  Change from baseline in SBP for all patients;

        -  Change from baseline in body weight;

        -  Proportion of patients with HbA1c &lt;6.5% and &lt;7.0%.

        -  To evaluate the safety of sotagliflozin versus placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study period is up to 87 weeks, including a Screening Period consisting
      of a Screening phase of up to 2 weeks and a 2 week single blind Run-in phase, a 26 week
      double-blind Core Treatment Period, a 53-week double-blind Extension Period, a 4 week post
      treatment Follow-up period to collect safety information.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in HbA1c</measure>
    <time_frame>Baseline to Week 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Change from Baseline in 2-hour PPG following a mixed meal - Time Frame: Baseline to Week 26 - Safety issue: No</measure>
    <time_frame>Baseline to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Change from Baseline in Fasting Plasma Glucose (FPG) - Time Frame: Baseline to Week 26 - Safety issue: No</measure>
    <time_frame>Baseline to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Change from Baseline in systolic blood pressure (SBP) for patients with baseline SBP ≥130 mmHg - Time Frame: Baseline to Week 12 - Safety issue: No</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Change from Baseline in SBP for all patients - Time Frame: Baseline to Week 12 - Safety issue: No</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Change from Baseline in body weight - Time Frame: Baseline to Week 26 - Safety issue: No</measure>
    <time_frame>Baseline to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Percentage of patients with HbA1c &lt;6.5% - Time Frame: At Week 26 - Safety issue: No</measure>
    <time_frame>At Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Percentage of patients with HbA1c &lt;7.0% - Time Frame: At Week 26 - Safety issue: No</measure>
    <time_frame>At Week 26</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sotagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A dose of sotagliflozin (SAR439954) will be administered as 2 tablets, once daily, before the first meal of the day. Metformin will be administered per Principal Investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A matching placebo will be administered as 2 tablets, once daily, before the first meal of the day. Metformin will be administered per Principal Investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sotagliflozin (SAR439954)</intervention_name>
    <description>Pharmaceutical form: tablet
Route of administration: oral</description>
    <arm_group_label>Sotagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: tablet
Route of administration: oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Pharmaceutical form: tablet
Route of administration: oral</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sotagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Patients with Type 2 Diabetes currently treated with diet and exercise and on
             metformin at a stable dose ≥1500 mg/day for at least 12 weeks. However, patients on
             metformin at a dose &lt;1500 mg/day at the time of enrollment (stable dose for at least
             12 weeks before enrollment) may be eligible for screening if documentation of lack of
             tolerance of a metformin dose ≥1500 mg/day can be provided.

          -  Signed written informed consent.

        Exclusion criteria:

          -  Age &lt;18 years at Screening or &lt; legal age of majority, whichever is greater.

          -  Type 1 diabetes mellitus.

          -  Body Mass Index (BMI) ≤20 or &gt;45 kg/m2 at Screening

          -  Hemoglobin A1c &lt;7% or &gt;10% via central laboratory test at screening.

          -  Fasting plasma glucose (FPG) &gt;15 mmol/L (270 mg/dL) measured by the central laboratory
             at screening (Visit 1) and confirmed by a repeat test (&gt;15 mmol/L [270 mg/dL]) before
             randomization.

          -  Women of childbearing potential not willing to use highly effective method(s) of birth
             control or who are unwilling or unable to be tested for pregnancy during the study.

          -  Treated with an antidiabetic pharmacological regimen other than metformin ≥1500 mg per
             day (or maximum tolerated dose) within the 12 weeks preceding the Screening Visit.

          -  Previous use of any types of insulin for &gt;1 month (at any time, aside from pregnancy
             for treatment of gestational diabetes).

          -  History of prior gastric surgical procedure, including gastric banding, within 3 years
             before the Screening Visit.

          -  History of diabetic ketoacidosis or nonketotic hyperosmolar coma within 12 weeks prior
             to the Screening Visit.

          -  Mean of 3 separate blood pressure measurements &gt;180 mmHg (SBP) or &gt;100 mmHg (diastolic
             blood pressure [DBP]).

          -  History of hypertensive urgency or emergency within 12 weeks prior to Screening.

          -  Patients with severe anemia, severe cardiovascular (including congestive heart failure
             New York Heart Association [NYHA] IV), respiratory, hepatic, neurological,
             psychiatric, or active malignant tumor or other major systemic disease or patients
             with short life expectancy making implementation of the protocol or interpretation of
             the study results difficult.

          -  Aspartate aminotransferase and/or alanine aminotransferase: &gt;3 times the upper limit
             of the normal laboratory range.

          -  Total bilirubin: &gt;1.5 times the upper limit of the normal laboratory range (except in
             case of Gilbert's syndrome).

          -  Use of systemic glucocorticoids (excluding topical or ophthalmic application or
             inhaled forms) for more than 10 consecutive days within 90 days prior to the Screening
             Visit.

          -  Patient who has taken other investigational drugs or prohibited therapy for this study
             within 12 weeks or 5 half-lives from screening or randomization, whichever is longer.

          -  Pregnant (confirmed by serum pregnancy test at Screening) or breastfeeding women.

          -  Patient is unwilling or unable to perform self-monitoring of blood glucose (SMBG),
             complete the patient diary, or comply with study visits and other study procedures as
             required per protocol.

          -  Contraindication to metformin as per local labeling.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>For site information, send an email with site number to</last_name>
    <email>Contact-Us@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 8402003</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402017</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402052</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018-8313</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402056</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303-1844</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402020</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92026-3923</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402028</name>
      <address>
        <city>Gold River</city>
        <state>California</state>
        <zip>95670-4344</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402067</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402025</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402051</name>
      <address>
        <city>La Mirada</city>
        <state>California</state>
        <zip>90638</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402011</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648-1839</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402014</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402066</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402029</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022-4302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402041</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036-4664</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402001</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402042</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950-7628</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402043</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-2209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402031</name>
      <address>
        <city>San Ramon</city>
        <state>California</state>
        <zip>94582-4826</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402047</name>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <zip>91356-3551</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402009</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402016</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117-5146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402035</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012-3407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402044</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012-7194</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402006</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402045</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402063</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33319-5800</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402060</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140-3608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402026</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402007</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402064</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33183-4825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402061</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186-5863</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402033</name>
      <address>
        <city>Opa-locka</city>
        <state>Florida</state>
        <zip>33054-3818</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402039</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32825-4454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402036</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143-5026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402038</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880-3053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402008</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31210-1359</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402054</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402022</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402069</name>
      <address>
        <city>Newton</city>
        <state>Iowa</state>
        <zip>50208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402059</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503-2502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402068</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808-4124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402012</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006-2930</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402053</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402037</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119-6302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402021</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852-4267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402062</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114-3755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402005</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402018</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401-1033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402002</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557-3126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402019</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402015</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97404-3233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402058</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446-1002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402030</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230-6885</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402050</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402010</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76164</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402040</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008-2436</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402065</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402057</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079-2212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402049</name>
      <address>
        <city>Magnolia</city>
        <state>Texas</state>
        <zip>77355</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402046</name>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <zip>79761-5133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402013</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402004</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402023</name>
      <address>
        <city>Schertz</city>
        <state>Texas</state>
        <zip>78154-1403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402027</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>84015-8638</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402032</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107-2518</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402024</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454-3075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8402034</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105-6008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1242005</name>
      <address>
        <city>Brampton</city>
        <zip>L6T 0G1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1242001</name>
      <address>
        <city>Calgary</city>
        <zip>T2H 2G4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1242002</name>
      <address>
        <city>Calgary</city>
        <zip>T2H 2G4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1242003</name>
      <address>
        <city>Calgary</city>
        <zip>T2H 2G4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1242004</name>
      <address>
        <city>Calgary</city>
        <zip>T2H 2G4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1242007</name>
      <address>
        <city>Calgary</city>
        <zip>T2H 2G4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1242013</name>
      <address>
        <city>Calgary</city>
        <zip>T2H 2G4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1242014</name>
      <address>
        <city>Calgary</city>
        <zip>T2H 2G4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1242008</name>
      <address>
        <city>Montreal</city>
        <zip>H3G 1L5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1242012</name>
      <address>
        <city>Newmarket</city>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1242010</name>
      <address>
        <city>Saint-Romuald</city>
        <zip>G6W 5M6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1242015</name>
      <address>
        <city>Toronto</city>
        <zip>M3M 3E5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1242006</name>
      <address>
        <city>Toronto</city>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1242011</name>
      <address>
        <city>Toronto</city>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3482002</name>
      <address>
        <city>Budapest</city>
        <zip>1033</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3482003</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3482006</name>
      <address>
        <city>Budapest</city>
        <zip>1213</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3482004</name>
      <address>
        <city>Debrecen</city>
        <zip>4025</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3482001</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3482007</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7032001</name>
      <address>
        <city>Bratislava</city>
        <zip>851 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7032005</name>
      <address>
        <city>Bratislava</city>
        <zip>851 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7032003</name>
      <address>
        <city>Malacky</city>
        <zip>901 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7032002</name>
      <address>
        <city>Nitra</city>
        <zip>949 11</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7032004</name>
      <address>
        <city>Sturovo</city>
        <zip>943 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7032006</name>
      <address>
        <city>Trencin</city>
        <zip>911 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Hungary</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2016</study_first_submitted>
  <study_first_submitted_qc>October 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2016</study_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

